Tier 3 Drug Shortages

Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:

  • a review of the information gathered on the shortage issue, and
  • a thorough discussion on its potential impact and next steps.

Below are the newest and most recently updated active ingredients that have been designated as Tier 3 shortages. Click on the active ingredient to see a list of the associated Tier 3 drug shortage and/or discontinuation reports.

Active Ingredient

14 active ingredients found

ASPARAGINASE - ERWINASE

powder for solution

Continuous Renal Replacement Therapy Solutions

solution

HYDRALAZINE INJECTION

solution

LEVOFLOXACIN INJECTION

solution

MEDROXYPROGESTERONE ACETATE

suspension

MORPHINE SULFATE

capsule (sustained-release)

MOXIFLOXACIN INJECTION

solution

PACLITAXEL

powder for suspension

PROPYLTHIOURACIL

tablet

SARILUMAB

solution

Showing 1 to 10 of 14